A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant
| Autor: | Gregor Winkels, Juliet Quirk, Eugene Maraskovsky, Lauren Seddon, Lisa M. Ebert, Jonathan Cebon, Tsin Yee Tai, Leone Morris, Frederick Wittke, Weisan Chen, Ian D. Davis, Judy Browning, Genevieve Whitty, Duncan MacGregor, Lena Miloradovic, Tina Cavicchiolo, Regina Alex, Heather Jackson |
|---|---|
| Přispěvatelé: | Davis, Ian D, Quirk, Juliet, Morris, Leone, Seddon, Lauren, Tai, Tsin Yee, Whitty, Genevieve, Cavicchiolo, Tina, Ebert, Lisa, Jackson, Heather, Browning, Judy, MacGregor, Duncan, Wittke, Frederick, Winkels, Gregor, Alex, Regina, Miloradovic, Lena, Maraskovsky, Eugene, Chen, Weisan, Cebon, Jonathan |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Skin Neoplasms medicine.medical_treatment T-Lymphocytes Pilot Projects Lymphocyte Activation Antigens CD1 antigens Immunology and Allergy Medicine NY-ESO-1 Neoplasm Metastasis Cells Cultured Phospholipids Antigen Presentation clinical trial Middle Aged Drug Combinations Cholesterol Treatment Outcome Oncology Female Immunotherapy Adjuvant Immunology Antigen presentation Cancer Vaccines 03 medical and health sciences Immune system Antigen Antigens Neoplasm Carcinoma Humans dendritic cells ISCOMATRIX™ adjuvant Aged Glycoproteins Neoplasm Staging Blood Cells business.industry Membrane Proteins Dendritic Cells Saponins medicine.disease Immunity Humoral Clinical trial 030104 developmental biology Carcinoma Basal Cell business Follow-Up Studies |
| Zdroj: | Immunotherapy. 9(3) |
| ISSN: | 1750-7448 |
| Popis: | Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|